An unfavorable ruling by a judge has scuttled an agreement in which Eli Lilly would have capped insulin prices and paid $13.5 million to resolve claims that it had inflated the drug's cost.
Lawyers for a proposed nationwide class of individuals, who paid for Lilly's Humalog injection and other insulin drugs, said in a filing in Newark, N.J. federal court that they and Lilly had decided not to go forward seeking approval for the deal.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Alan Goforth
Alan Goforth is a freelance writer in suburban Kansas City. In addition to freelancing for several publications, he has written a dozen books about sports and other topics.
